BIOLINERX Ltd/S (NASDAQ:BLRX) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.06), Morningstar.com reports.

Shares of BIOLINERX Ltd/S stock traded down $0.01 during trading on Friday, reaching $0.70. 391,694 shares of the company traded hands, compared to its average volume of 1,728,884. BIOLINERX Ltd/S has a 1-year low of $0.67 and a 1-year high of $1.84. The company has a market capitalization of $78.77 million, a PE ratio of -2.59 and a beta of 0.87.

A hedge fund recently bought a new stake in BIOLINERX Ltd/S stock. Fosun International Ltd bought a new stake in shares of BIOLINERX Ltd/S (NASDAQ:BLRX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned 1.27% of BIOLINERX Ltd/S as of its most recent SEC filing. Institutional investors own 34.69% of the company’s stock.

A number of research analysts have recently issued reports on BLRX shares. ValuEngine upgraded shares of BIOLINERX Ltd/S from a “hold” rating to a “buy” rating in a research report on Thursday, October 4th. HC Wainwright set a $4.00 price target on shares of BIOLINERX Ltd/S and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Zacks Investment Research upgraded shares of BIOLINERX Ltd/S from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research report on Thursday, August 16th. Maxim Group restated a “buy” rating and issued a $2.00 price target on shares of BIOLINERX Ltd/S in a research report on Monday, August 13th. Finally, Oppenheimer set a $3.00 price target on shares of BIOLINERX Ltd/S and gave the stock a “buy” rating in a research report on Friday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. BIOLINERX Ltd/S currently has a consensus rating of “Buy” and a consensus target price of $2.50.

COPYRIGHT VIOLATION WARNING: “BIOLINERX Ltd/S (BLRX) Releases Earnings Results, Meets Estimates” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2018/11/10/biolinerx-ltd-s-blrx-releases-earnings-results-meets-estimates.html.

About BIOLINERX Ltd/S

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Further Reading: Rule of 72

Earnings History for BIOLINERX Ltd/S (NASDAQ:BLRX)

Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.